The IMpassion130 trial demonstrated that the combination of the PD-L1 inhibitor atezolizumab with nab-paclitaxel significantly prolonged the overall survival (OS) of PD-L1-positive patients with advanced triple-negative breast cancer (TNBC) (Ahmed et al., 2020). Here, CD274 is linked to triple-negative breast carcinoma.